dc.creatorTERZIAN, Ana Luisa B.
dc.creatorAGUIAR, Daniele C.
dc.creatorGUIMARAES, Francisco S.
dc.creatorMOREIRA, Fabricio A.
dc.date.accessioned2012-10-19T22:51:51Z
dc.date.accessioned2018-07-04T15:16:30Z
dc.date.available2012-10-19T22:51:51Z
dc.date.available2018-07-04T15:16:30Z
dc.date.created2012-10-19T22:51:51Z
dc.date.issued2009
dc.identifierEUROPEAN NEUROPSYCHOPHARMACOLOGY, v.19, n.3, p.188-195, 2009
dc.identifier0924-977X
dc.identifierhttp://producao.usp.br/handle/BDPI/24195
dc.identifier10.1016/j.euroneuro.2008.11.004
dc.identifierhttp://dx.doi.org/10.1016/j.euroneuro.2008.11.004
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1620923
dc.description.abstractThe endocannabinoid anandamide is a possible agonist at the Transient Receptor Potential Vanilloid Type 1 (TRPV1) channel, in addition to its agonist activity at cannabinoid type 1 (CB1) receptor. In the midbrain dorsolateral periaqueductal gray (dlPAC) our previous data showed that CB1 activation induces anxiolytic-like effects. However, the rote of TRPV1 has remained unclear. Thus, in the present study we tested the hypothesis that this channel would contribute to the modulation of anxiety-like behaviour in the dlPAG. Mate Wistar rats received local injections of the TRPV1 antagonist capsazepine (10-60 nmol) and were submitted to the elevated plus-maze (EPM) and to the Vogel test. In addition, animals received local injections of capsaicin (0.01-1nmol), a TRPV1 agonist, and were tested in the same models. In accordance with our hypothesis, capsazepine produced anxiolytic-like effects both in the EPM and in the Vogel test. Capsaicin mimicked these results, which might be attributed to its ability to quickly desensitize the channel. Altogether, our data suggest that, while CB1 receptors seem to inhibit aversive responses in the dlPAG, TRPV1 could facilitate them. Thus, CB1 and TRPV1 may have opposite functions in modulating anxiety-like behaviour in this region. (C) 2008 Elsevier B.V. and ECNP. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCIENCE BV
dc.relationEuropean Neuropsychopharmacology
dc.rightsCopyright ELSEVIER SCIENCE BV
dc.rightsrestrictedAccess
dc.subjectAnandamide
dc.subjectEndocannabinoids
dc.subjectEndovanilloids
dc.subjectAnxiety
dc.subjectElevated plus-maze
dc.subjectVogel test
dc.titleModulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución